Galapagos (France)

Recent papers from Galapagos (France)

1. Redirection of the Beckmann Rearrangement to Form Pyrrolidino[1,2- a ]benzimidazoles and Application to an Independent Synthetic Route to the Core of BalinatunfibThe Journal of Organic Chemistry · 2026
2. Inhibition of Salt-Inducible Kinases 2 and 3 reduces inflammatory signature in PsoriasisJournal of Investigative Dermatology · 2026
3. Efficacy and safety of the cystic fibrosis transmembrane conductance regulator inhibitor GLPG2737 for autosomal dominant polycystic kidney disease: phase 2a MANGROVE studyNephrology Dialysis Transplantation · 2026
4. Pharmacological Characterization of GLPG3667, a Tyrosine Kinase 2-Selective Inhibitor, for the Treatment of Inflammatory and Autoimmune DiseasesInflammation · 2026
5. Quantum Nanoplatelet Pixelation at 3000 PPI for Enhanced Color Conversion in Microdisplay Applications: Direct Integration on MicroLEDsAdvanced Optical Materials · 2026
6. Selective SIK2/SIK3 inhibition reprograms pro- and antiinflammatory pathways in myeloid cells, improving autoimmune disease outcomesJCI Insight · 2026
7. Discovery and Characterization of GLPG3808, a PAPD5/7 Inhibitor for Suppression of Hepatitis B Viral InfectionsJournal of Medicinal Chemistry · 2026
8. HBsAg Suppression by a New Series of HBV RNA Destabilizers: Discovery and Effects on In Vitro Neurite OutgrowthJournal of Medicinal Chemistry · 2026
9. Targeted Delivery of Oligonucleotide–Peptide Conjugates for Enhanced Kidney-Specific TherapyJournal of Medicinal Chemistry · 2025
10. Structure–Activity Relationship Guided Scaffold Hopping Resulted in the Identification of GLPG4970, a Highly Potent Dual SIK2/SIK3 InhibitorJournal of Medicinal Chemistry · 2025
11. Computational Hit Finding: An Industry PerspectiveJournal of Medicinal Chemistry · 2025
12. Design, Synthesis, and Biological Implications of Autotaxin inhibitors with a Three-Point lock binding modeBioorganic & Medicinal Chemistry · 2025
13. Evaluation of BCRP-Related DDIs Between Methotrexate and Cyclosporin A Using Physiologically Based Pharmacokinetic ModellingDrugs in R&D · 2024
14. Design of a potent and selective dual JAK1/TYK2 inhibitorBioorganic & Medicinal Chemistry · 2024
15. Prediction of Disease Progression and Clinical Response in Systemic Sclerosis: Experience From a Proof‐of‐Concept TrialACR Open Rheumatology · 2024
16. Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune DiseasesJournal of Medicinal Chemistry · 2024
17. Discovery of Clinical Candidate GLPG3970: A Potent and Selective Dual SIK2/SIK3 Inhibitor for the Treatment of Autoimmune and Inflammatory DiseasesJournal of Medicinal Chemistry · 2024
18. Discovery of GLPG2737, a Potent Type 2 Corrector of CFTR for the Treatment of Cystic Fibrosis in Combination with a Potentiator and a Type 1 Co-correctorJournal of Medicinal Chemistry · 2024
19. Optimization of Selectivity and Pharmacokinetic Properties of Salt-Inducible Kinase Inhibitors that Led to the Discovery of Pan-SIK Inhibitor GLPG3312Journal of Medicinal Chemistry · 2023
20. ISABELA Studies: Plasma Exposure and Target Engagement Do Not Explain the Lack of Efficacy of Ziritaxestat in Patients with Idiopathic Pulmonary FibrosisClinical Pharmacology & Therapeutics · 2023